Ma, W. W., Nelson, G. D., Tran, N. H., Crysler, O. V., Iyer, R., Morse, M., Washburn, L., Fonkoua, L. A. K., Fountzilas, C., Sonbol, M. B., Peersen, A., Sahai, V., Mohan, A., Ou, F., Bekaii-Saab, T. S. (2026). A phase II randomized study of atezolizumab plus multikinase inhibitor (MKI) versus MKI alone in patients with advanced hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab (Atezo/Bev).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.554